Is there actually a proven benefit of intensive blood glucose control in patients who have diabetes, and if there is what actually is that benefit? In this 8-minute podcast, Drs. Jack Leahy and Doron Schneider answer this question based on data from The Diabetes Control and Complications study.
- Posted August 4, 2014 by John L. Leahy, MD
- Posted June 18, 2014 by John L. Leahy, MD
The results of the Diabetes Control and Complications Trial (DCCT) showed an outstanding benefit of almost 70 percent reduction in microvascular disease when driving down A1C to 7, but also showed a higher frequency of hypoglycemia -- events that patients don’t forget. "It was clear intensive therapy back then came with a significant price."
- Posted July 24, 2013 by John L. Leahy, MDTags:
- Posted June 12, 2013 by John L. Leahy, MD
Doron Schneider, MD and Jack Leahy, MD discuss the importance of patient BMI and other risk factors for coronary artery disease when weighing treatment options.
- Posted May 29, 2013 by John L. Leahy, MDTags:
Dr. Jack Leahy, endocrinologist and general internist, Dr. Doron Schneider, weigh different initial treatment options presented by leading endocrinologists Silvio Inzucchi, MD, Alan J. Garber, MD and Laurence Kennedy, MD
- Posted January 17, 2013 by John L. Leahy, MD(Full disclosure – I am an Advisor to Janssen pharmaceuticals that makes canagliflozin)An FDA advisory panel last week reviewed canagliflozin, with the majority recommending approval. Canaglifozin is the first member of a new class of oral medications for type 2 diabetes–sodium-glucose co-transportor-2 (SGLT2) inhibitors–that will likely make it to the U.S. market.
The Good, The Bad, and the Ugly Part II: Why I’m not a Fan of the ADA/EASD’s 2012 Position StatementPosted June 6, 2012 by John L. Leahy, MDTags:
- Posted May 30, 2012 by John L. Leahy, MDTags:The highly awaited ADA/EASD statement on management of type 2 diabetes was published online April 19th, 2012.1 I feel like a curmudgeon,but as a general statement, I’m not a fan. In fact, I’m worried that at best it will have little impact, and at worst could be harmful.
- Posted March 28, 2012 by John L. Leahy, MDTags:
In the past decade or so, our attempts to define the "earliest” events in Type 2 diabetes (T2DM) have moved increasingly earlier. We’re considering even the years before what we now consider to be the “pre-diabetes” stage—that is, years considerably before there are any clinical signs or symptoms of disease.
- Page 1 of 2